This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): tapentadol immediate release (IR), R331333, CG5503, JNS024, Palexia, Palexis
Description: BioMedTracker has separate drug profiles for the immediate release (IR) and extended release (ER) formulations of Tapentadol. Please also see Tapentadol ER.
Tapentadol is a centrally acting analgesic with a dual mechanism of action (opioid receptor agonist and norepinepheron re-uptake inhibitor).
Ortho-McNeil and Grnenthal
In February 2003, Ortho-McNeil Pharmaceuticals, a subsidiary of Johnson & Johnson, entered into a licensing agreement for tapentadol with Grnenthal for tapentadol. Under the agreement, Johnson & Johnson Pharmaceutical Research & Development is co-developing the product with Grnenthal in the United States and Canada.
In January 2007, Grnenthal extended the licensing agreement with Ortho-McNeil for tapentadol to include the Japanese market. Ortho-McNeil plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil's affiliate, Janssen Pharmaceutical K.K., will conduct such activities. Grnenthal will be responsible for the commercial supply of tapentadol for Japan.
In June 2010, Janssen Pharmaceutica announced it expanded its licensing agreement with the Grnenthal to register, manufacture and commercialize Tapentadol in additional regions, including new European countries such as Turkey and Greece, under...See full deal structure in Biomedtracker
Partners: Grünenthal GmbH Shire Pharmaceuticals Group PLC
Pink Sheet FDA Approvals, In Brief
Additional information available to subscribers only: